HOME >> MEDICINE >> NEWS
American Heart Association Comment On New England Journal Of Medicine Report OnCalcium Antagonist Nisoldipine (March 5 issue)

A study in the NEJM titled "The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension," finds an increased risk of fatal and non-fatal heart attacks among individuals taking the calcium antagonist nisoldipine compared to individuals taking enalapril, which is a member of a class of drugs called ACE-inhibitors.

The study provides more evidence that calcium antagonists (preferred term for calcium channel blockers) may pose risks for certain people, including those with diabetes and coronary heart disease. Past studies of short-acting calcium antagonists have also found increased risk of cardiovascular complications. It was thought that the longer-acting drugs did not pose similar risks. However, the current study used a long-acting drug.

Speaking for the American Heart Association, Joseph Izzo, M.D., says "individuals taking calcium antagonists should not panic and stop medication without consulting a physician. However, individuals with both known cardiovascular disease and diabetes may want to talk to their physicians about choosing another type of high blood pressure drug, or to use the calcium antagonist in combination with other agents that are complementary." Izzo is a member of the American Heart Association's Continuing Education Committee.

Calcium antagonists dilate (relax) constricted blood vessels and thus reduce blood pressure. However, this vasodilator action may force the heart to pump harder and may also stimulate stress hormones. This action is the opposite of beta-blockers that limit cardiac output, notes Izzo, professor of medicine and pharmacology at the State University of New York, Buffalo.

The study, by Raymond Estacio, M.D., of the Colorado Prevention Center, Denver, included 470 individuals who had high blood pressure and non-insulin dependent diabetes. The trial compared an ACE-inhibitor with a calcium antagonist in the p
'"/>

Contact: Carole Bullock
caroleb@amhrt.org
214-705-1279
American Heart Association
3-Mar-1998


Page: 1 2

Related medicine news :

1. Consumers with disabilities empowered by American Disabilities Act
2. Definition of persistent vegetative state available from American Academy of Neurology
3. African-American women with endometrial cancer have more aggressive cancer than Caucasian women
4. New colorectal cancer screening recommendations for African Americans
5. American Thoracic Society Journal news tips for March 2005 (second issue)
6. Community care tops medical care at preventing heart disease in black Americans
7. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
8. Obesity among African-American stroke survivors increases risk factors for recurrent stroke
9. Awards & fellowships at the International & American Association for Dental Research General Session
10. American Academy of Neurology presents 57th Annual Meeting in Miami Beach
11. News tips from the 2005, 54th Annual Scientific Sessions of the American College of Cardiology

Post Your Comments:
(Date:10/31/2014)... 2014 Daily Gossip writes in its Xtreme ... as the fastest fat loss program ever developed. It promises ... month. , There is no wonder after all that this ... time. The new nutrition and workout fat loss program was ... , According to the author of this fat loss ...
(Date:10/31/2014)... Lake City, UT (PRWEB) October 31, 2014 ... announce the new Activz Silver line offering ... and cleansing wipes. For over a century, silver has ... formula found in Activz Silver products is the most ... U.S. patents, has a unique chemical structure that supports ...
(Date:10/31/2014)... In terms of duration of treatment and cost, ... from accelerated partial breast irradiation (APBI) with proton ... new research from The University of Texas MD ... a cost analysis study based on typical patient ... allowable charges for eight different types of partial ...
(Date:10/31/2014)... 31, 2014 The Suspension Revolution review ... program was developed by Dan Long, a suspension training ... a fitness professional and life coach. The author of ... toned muscles is not impossible , The Suspension Revolution ... training. Suspension training promises efficiency when it comes to ...
(Date:10/31/2014)... FindSurrogateMother.com conveys a refreshing ... life — building a family through surrogacy. The company ... donors with hopeful intended parents in turn generating thousands ... a collective aptitude of surrogate mothers, intended parents, egg ... clinics that help provide these connections — and a ...
Breaking Medicine News(10 mins):Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3
(Date:10/31/2014)... , Oct. 31, 2014 ThynkWare ( www.thynkware.com ... patients initiate text and email messages using their thoughts. ... technology invented by ThynkWare,s founder, Duane Cash , ... smartphone device. This technology allows users to control their ... power of thought. ThynkWare provides the interface ...
(Date:10/31/2014)... ANGELES , Oct. 30, 2014 Migranade, ... Relief will be available to the 36 million U.S. ... a platform technology that targets the actual cause of ... medications attack pain and not the source Migranade is ... medication category. MIGRANADE Migraine Relief is available at ...
(Date:10/31/2014)...  AbbVie (NYSE: ABBV ) today ... Sept. 30, 2014. "Our third-quarter ... with double-digit growth from HUMIRA and several other ... percent in the quarter excluding lipids," said Richard ...  "We exceeded our outlook for the quarter and ...
Breaking Medicine Technology:ThynkWare Speech Helps Those with ALS and Locked-In Syndrome Translate Thought to Speech on Their Smartphone Devices 2Game Changing Migraine Medication To Be Available November 2014 2AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24
Cached News: